目的评价培美曲塞联合香菇多糖对初治肺腺癌并恶性心包积液的临床疗效和不良反应。方法 30例病理确诊初治肺腺癌并恶性心包积液患者,随机分入培美曲赛联合香菇多糖局部灌注组及顺铂局部灌注组;两周期后评价疗效。结果 30例可评价,两组总RR分别为:66.6%和86.6%两组比较无统计学差异;中位无疾病进展生存期分别为:(8.076±0.456)个月和(5.122±0.335)个月,差异具有统计学意义。结论培美曲塞联合香菇多糖一线治疗的肺腺癌并恶性心包积液患者,具有较好的疗效和安全性。 Objective To evaluate the clinical efficacy and adverse reactions of pemetrexed combined with lentinan on newly diagnosed lung adenocarcinoma with malignant pericardial effusion. Methods Thirty patients with newly diagnosed lung adenocarcinoma and malignant pericardial effusion diagnosed by pathology were randomly divided into pemetrexed combined with lentinan and cisplatin local perfusion group. The curative effect was evaluated after two cycles. Results 30 cases were evaluable. The total RR of the two groups was 66.6% and 86.6%, respectively. There was no significant difference between the two groups. The median progression-free survival was (8.076 ± 0.456) months and (5.122 ± 0.335) months Month, the difference was statistically significant. Conclusion Pemetrexed combined with lentinan in the treatment of patients with lung adenocarcinoma and malignant pericardial effusion has good curative effect and safety.